Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWRNASDAQ:GMTXNASDAQ:VCELNASDAQ:XNCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$16.82+8.1%$13.34$9.57▼$30.41$2.32B0.891.51 million shs3.07 million shsGMTXGemini Therapeutics$45.12-1.7%$45.48$1.16▼$14.10$1.95B-0.12189,291 shs274,276 shsVCELVericel$41.35-1.8%$41.77$37.39▼$63.00$2.08B1.31411,817 shs670,573 shsXNCRXencor$7.74+2.5%$9.34$7.16▼$27.24$550.86M0.99659,382 shs1.12 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals+1.24%+1.63%+15.09%-17.85%-34.95%GMTXGemini Therapeutics-3.15%-8.39%+1.01%-15.75%+33.84%VCELVericel+0.07%+2.51%+8.67%-15.16%-12.24%XNCRXencor-2.58%+0.40%-28.77%-49.60%-67.74%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARWRArrowhead Pharmaceuticals3.8241 of 5 stars3.32.00.03.43.52.50.0GMTXGemini TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVCELVericel2.9288 of 5 stars3.53.00.00.02.20.81.9XNCRXencor3.9854 of 5 stars3.41.00.03.93.70.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 2.67Moderate Buy$42.13150.45% UpsideGMTXGemini Therapeutics 0.00N/AN/AN/AVCELVericel 3.00Buy$61.1447.87% UpsideXNCRXencor 2.89Moderate Buy$29.50281.14% UpsideCurrent Analyst Ratings BreakdownLatest XNCR, ARWR, VCEL, and GMTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025VCELVericelStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.005/20/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/13/2025ARWRArrowhead PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$21.00 ➝ $17.005/13/2025ARWRArrowhead PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.005/8/2025XNCRXencorBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$22.00 ➝ $6.004/30/2025XNCRXencorWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$31.004/21/2025XNCRXencorWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/11/2025VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$61.00 ➝ $51.003/3/2025VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$67.00 ➝ $61.002/28/2025VCELVericelHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.002/28/2025XNCRXencorWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$37.00 ➝ $33.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$545.21M4.26N/AN/A$1.54 per share10.92GMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/AVCELVericel$238.54M8.73$0.01 per share3,081.95$4.73 per share8.74XNCRXencor$127.23M4.33N/AN/A$10.99 per share0.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$599.49M-$1.40N/AN/AN/AN/A-236.60%-64.09%8/14/2025 (Estimated)GMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/AVCELVericel-$3.18M$0.03689.2893.98N/A1.56%1.48%0.96%8/7/2025 (Estimated)XNCRXencor-$126.09M-$3.06N/AN/AN/A-232.77%-30.92%-21.74%8/4/2025 (Estimated)Latest XNCR, ARWR, VCEL, and GMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q2 2025ARWRArrowhead Pharmaceuticals-$0.06$2.75+$2.81$2.75$116.27 million$542.71 million5/8/2025Q1 2025VCELVericel-$0.09-$0.23-$0.14-$0.23$53.86 million$52.60 million5/8/2025Q1 2025XNCRXencor-$0.60-$0.66-$0.06-$0.66$23.44 million$32.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/AXNCRXencorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals7.276.096.09GMTXGemini TherapeuticsN/A71.4971.49VCELVericelN/A4.614.23XNCRXencor0.016.236.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%GMTXGemini Therapeutics75.42%VCELVericelN/AXNCRXencorN/AInsider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals4.30%GMTXGemini Therapeutics12.90%VCELVericel5.20%XNCRXencor4.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400138.10 million120.68 millionOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableVCELVericel30050.34 million46.79 millionOptionableXNCRXencor28071.17 million66.32 millionOptionableXNCR, ARWR, VCEL, and GMTX HeadlinesRecent News About These CompaniesXencor, Inc. (NASDAQ:XNCR) Shares Sold by Two Sigma Investments LPMay 27 at 4:23 AM | marketbeat.comNuveen Asset Management LLC Purchases 685,557 Shares of Xencor, Inc. (NASDAQ:XNCR)May 26 at 3:54 AM | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Holdings Lowered by Jane Street Group LLCMay 26 at 3:12 AM | marketbeat.comTwo Sigma Advisers LP Sells 130,900 Shares of Xencor, Inc. (NASDAQ:XNCR)May 25, 2025 | marketbeat.comAmeriprise Financial Inc. Has $6.72 Million Stake in Xencor, Inc. (NASDAQ:XNCR)May 25, 2025 | marketbeat.comXencor (NASDAQ:XNCR) vs. Dermata Therapeutics (NASDAQ:DRMA) Financial ComparisonMay 19, 2025 | americanbankingnews.comXencor, Inc. (NASDAQ:XNCR) Shares Acquired by RTW Investments LPMay 18, 2025 | marketbeat.comPoint72 Asset Management L.P. Sells 943,148 Shares of Xencor, Inc. (NASDAQ:XNCR)May 18, 2025 | marketbeat.comNorthern Trust Corp Increases Holdings in Xencor, Inc. (NASDAQ:XNCR)May 17, 2025 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 16, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Raises Stock Position in Xencor, Inc. (NASDAQ:XNCR)May 15, 2025 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA)May 13, 2025 | theglobeandmail.comLeerink Partnrs Has Bearish Forecast for Xencor Q2 EarningsMay 13, 2025 | marketbeat.comWedbush Comments on Xencor's Q2 Earnings (NASDAQ:XNCR)May 13, 2025 | marketbeat.comResearch Analysts Set Expectations for Xencor Q2 EarningsMay 13, 2025 | marketbeat.comDeep Track Capital LP Has $11.49 Million Stake in Xencor, Inc. (NASDAQ:XNCR)May 9, 2025 | marketbeat.comBraidwell LP Buys 149,083 Shares of Xencor, Inc. (NASDAQ:XNCR)May 8, 2025 | marketbeat.comXencor Reports First Quarter 2025 Financial ResultsMay 7, 2025 | uk.finance.yahoo.comXencor (XNCR) Reports Q1 Loss, Tops Revenue EstimatesMay 7, 2025 | zacks.comXencor (NASDAQ:XNCR) Trading Down 6.1% - Should You Sell?May 7, 2025 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) EVP Nancy Valente Sells 4,616 SharesMay 7, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXNCR, ARWR, VCEL, and GMTX Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$16.82 +1.26 (+8.10%) Closing price 04:00 PM EasternExtended Trading$16.85 +0.03 (+0.18%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Gemini Therapeutics NASDAQ:GMTX$45.12 -0.76 (-1.66%) As of 05/28/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Vericel NASDAQ:VCEL$41.35 -0.75 (-1.78%) Closing price 04:00 PM EasternExtended Trading$41.36 +0.01 (+0.02%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.Xencor NASDAQ:XNCR$7.74 +0.19 (+2.52%) Closing price 04:00 PM EasternExtended Trading$7.68 -0.07 (-0.84%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
